Takeda Pharmaceutical (TAK) Net Margin (2017 - 2026)
Takeda Pharmaceutical's (TAK) quarterly Net Margin came in at 33.66% in Q1 2026, down 4395.0% year-on-year from 0.78% in Q1 2025, and little changed quarter-over-quarter from 33.66% in Q4 2025.
Takeda Pharmaceutical (TAK) Net Margin (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Net Margin history runs 10 years deep, the most recent figure standing at 33.66% for Q1 2026.
- On a quarterly basis, Net Margin fell 4395.0% year-over-year to 33.66% in Q1 2026; TTM through Mar 2026 was 5.72%, a 1040.0% decrease from a year earlier, with the FY2026 full-year figure at 3.38%, down 574.0% from the prior year.
- Net Margin was little changed at 33.66% in Q1 2026 per TAK's latest filing, from 33.66% in the prior quarter.
- Across five years, Net Margin topped out at 10.86% in Q4 2022 and bottomed at 33.66% in Q1 2026.
- The 5-year median for Net Margin is 7.82% (2025), against an average of 1.41%.
- Across the five-year window, Net Margin soared 1109 bps in 2023 and sank 4395 bps in 2026, its largest moves.
- Year by year, Net Margin stood at 10.86% in 2022, then tumbled by 73 bps to 2.96% in 2023, then sank by 431 bps to 9.8% in 2024, then sank by 244 bps to 33.66% in 2025, then dropped by 0 bps to 33.66% in 2026.
- Per Business Quant, the three latest TAK Net Margin figures stand at 33.66% (Q1 2026), 33.66% (Q4 2025), and 6.12% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 9.29% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 26.57% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -33.66% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 35.18% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 5.03% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 24.30% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 4.16% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -21.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.66% |
| Dec 31, 2025 | -33.66% |
| Sep 30, 2025 | 6.12% |
| Jun 30, 2025 | 7.82% |
| Mar 31, 2025 | 10.28% |
| Dec 31, 2024 | -9.80% |
| Sep 30, 2024 | 5.98% |
| Jun 30, 2024 | 7.88% |
| Mar 31, 2024 | 7.88% |
| Dec 31, 2023 | 2.96% |
| Sep 30, 2023 | 2.78% |
| Jun 30, 2023 | 8.44% |
| Mar 31, 2023 | 9.92% |
| Dec 31, 2022 | 10.86% |
| Sep 30, 2022 | 10.48% |
| Jun 30, 2022 | 10.80% |
| Mar 31, 2022 | -1.17% |
| Dec 31, 2021 | 6.41% |
| Sep 30, 2021 | 5.44% |
| Jun 30, 2021 | 14.50% |